We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
AvactaDiagnostics build-out continues with Coris acquisition
Redx PharmaTwo key Phase II results on track for next 12 months
Redx PharmaROCK solid start in cancer-associated fibrosis
AvactaBuilding on Therapeutic and Diagnostic foundations
AvactaFY22 results point to progress across Tx and Dx
ANGLERecent deals provide evidence of assay traction
Arecor TherapeuticsContinued delivery with key AT278 data due in Q423
Futura MedicalGearing up for further launches in 2023
Redx PharmaFundamentals intact with catalysts on the horizon
HUTCHMEDSignificant 2022 achievements catalyse a promising 2023